Published in
Elsevier, Clinical Lymphoma, Myeloma and Leukemia, 3(22), p. 198-204, 2022
DOI: 10.1016/j.clml.2021.09.018
Links
Tools
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience
Journal article published in 2022 by
Marina Moretti 
,
Anna Marina Liberati,
Luigi Rigacci ,
Benedetta Puccini,
Alessandro Pulsoni ,
Guido Gini,
Piero Galieni,
Alberto Fabbri ,
Maria Cantonetti,
Vincenzo Pavone,
Silvia Bolis,
Barbara Botto,
Daniela Renzi,
Lorenzo Falchi
,
Anna Marina Liberati,
Luigi Rigacci ,
Benedetta Puccini,
Alessandro Pulsoni ,
Guido Gini,
Piero Galieni,
Alberto Fabbri ,
Maria Cantonetti,
Vincenzo Pavone,
Silvia Bolis,
Barbara Botto,
Daniela Renzi,
Lorenzo Falchi
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 